Back to resultsA Study for the Treatment of Hormone Refractory Prostate Cancer (HRPC) in Patients Previously Treated With Chemotherapy
Primary Purpose
Prostate Cancer, Cancer of Prostate, Prostatic Cancer
Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
YM155
Sponsored by
About this trial
This is an interventional treatment trial for Prostate Cancer focused on measuring Treatment Efficacy, Treatment Effectiveness, Disease Management, Treatment, Safety
Eligibility Criteria
Inclusion Criteria: Histologically or cytologically confirmed prostate cancer. Prior chemotherapy regimen for prostate cancer Exclusion Criteria: History of other malignancy in the last 5 years Major surgery within the past 21 days
Sites / Locations
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
NCT ID
NCT00257478
First Posted
November 22, 2005
Last Updated
June 6, 2012
Sponsor
Astellas Pharma Inc
Collaborators
Astellas Pharma US, Inc.
1. Study Identification
Unique Protocol Identification Number
NCT00257478
Brief Title
A Study for the Treatment of Hormone Refractory Prostate Cancer (HRPC) in Patients Previously Treated With Chemotherapy
Study Type
Interventional
2. Study Status
Record Verification Date
June 2012
Overall Recruitment Status
Completed
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
March 2007 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Astellas Pharma Inc
Collaborators
Astellas Pharma US, Inc.
4. Oversight
5. Study Description
Brief Summary
A study for the treatment of hormone refractory prostate cancer (HRPC) in patients previously treated with chemotherapy.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Prostate Cancer, Cancer of Prostate, Prostatic Cancer, Cancer of the Prostate
Keywords
Treatment Efficacy, Treatment Effectiveness, Disease Management, Treatment, Safety
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
YM155
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Histologically or cytologically confirmed prostate cancer.
Prior chemotherapy regimen for prostate cancer
Exclusion Criteria:
History of other malignancy in the last 5 years
Major surgery within the past 21 days
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
D. Buell, MD
Organizational Affiliation
Astellas Pharma US, Inc.
Official's Role
Study Director
Facility Information:
City
Tuscon
State/Province
Arizona
ZIP/Postal Code
85724
Country
United States
City
Los Angeles
State/Province
California
ZIP/Postal Code
90033
Country
United States
City
Coeur d'Alene
State/Province
Idaho
ZIP/Postal Code
83814
Country
United States
City
Bronx
State/Province
New York
ZIP/Postal Code
10461
Country
United States
City
New York
State/Province
New York
ZIP/Postal Code
10016
Country
United States
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19111
Country
United States
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78229
Country
United States
City
Amsterdam
Country
Netherlands
City
Sutton
State/Province
Surry
ZIP/Postal Code
SM2 5Pt
Country
United Kingdom
12. IPD Sharing Statement
Learn more about this trial
A Study for the Treatment of Hormone Refractory Prostate Cancer (HRPC) in Patients Previously Treated With Chemotherapy
We'll reach out to this number within 24 hrs